Sera Prognostics Highlights Financial Progress for 2024
Sera Prognostics Reports Fourth Quarter 2024 Financial Results
Sera Prognostics Inc., known as The Pregnancy Company (NASDAQ: SERA), focuses on enhancing maternal and neonatal health by providing innovative pregnancy biomarker information to healthcare professionals and patients. The company has recently announced its financial outcomes for the fourth quarter and the entire year ending December 31, 2024.
Recent Developments in Maternal Healthcare
In a significant step for maternal and fetal medicine, the Society for Maternal Fetal Medicine published pivotal findings related to Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal Outcomes (PRIME) study. This research, showcasing key results, was notably featured at the prestigious SMFM 2025 Pregnancy Meeting, where expert Dr. Brian Iriye led discussions on the advancements made.
Presentation of Key Findings
Dr. Iriye's presentation highlighted critical findings from the PRIME study, revealing that both primary outcomes achieved significant success, showing a 25% reduction in neonatal morbidity and mortality index (NMI) and an 18% reduction in hospital stay among the modified intent-to-treat population. Moreover, broader findings indicated a 20% reduction in NMI and 22% reduction in NICU admissions.
Financial Performance Overview
For the fourth quarter of 2024, Sera recorded revenues of $24,000, reflecting a decrease from $41,000 in the same quarter of 2023. Operating expenses for the same period were reported at $9.4 million, an increase from $8.9 million the previous year as the company strategically invests in future product development and commercialization efforts.
Investment in Growth
Research and development expenses amounted to $3.1 million for Q4 2024, a reduction of 19% compared to the prior year. Meanwhile, the selling, general, and administrative expenses rose to $6.3 million, up from $5.0 million, driven by enhanced commercial activities aimed at stimulating future growth.
Annual Financial Highlights
Looking at the broader picture, total revenue for 2024 was recorded at $77,000, a decrease from $306,000 in 2023, reflecting the company's evolving market strategy. Operating expenses throughout 2024 totaled $36.7 million, showing an effective cost management strategy as opposed to the previous year’s $40.1 million. Importantly, Sera's net loss for 2024 was reported at $32.9 million, a marked improvement compared to the $36.2 million loss in 2023.
Enhancing Financial Stability
As of December 31, 2024, Sera had cash and equivalents of approximately $68.2 million. With recent fundraising efforts concluding in February 2025 by raising $57.5 million through a follow-on public offering, Sera has fortified its financial runway into 2028. This funding is intended to facilitate the adoption and commercialization of Sera’s PreTRM test, significantly improving its value proposition in the marketplace.
Upcoming Conferencing Initiatives
Sera Prognostics will host an engaging conference call, providing insights into the fourth quarter and annual results, as well as discussing strategic directions. Dialing in from anywhere is simple: domestic callers may use (800) 836-8184 and international attendees can connect via (646) 357-8785.
About Sera Prognostics, Inc.
Sera Prognostics is committed to advancing health diagnostics aimed at improving the well-being of women and infants through precision pregnancy services. The company is dedicated to delivering early and crucial pregnancy insights that enhance healthcare outcomes for mothers and newborns while curbing rising healthcare costs. Through its innovative PreTRM Test, which evaluates the individual risk of premature delivery in pregnancies, Sera enables proactive healthcare strategies for higher risk patients. Based in Salt Lake City, Utah, Sera is making significant strides in maternal healthcare.
Frequently Asked Questions
What is Sera Prognostics?
Sera Prognostics is a leading health diagnostics company focused on improving maternal and neonatal health through innovative pregnancy biomarkers.
What did Sera announce for Q4 2024?
During Q4 2024, Sera reported a revenue of $24,000 and a net loss of $8.6 million, showcasing strategic cost management efforts.
How has Sera's financial performance changed over the past year?
Sera's annual revenue decreased from $306,000 in 2023 to $77,000 in 2024, but the overall net loss decreased from $36.2 million to $32.9 million.
What recent developments occurred in maternal-fetal medicine?
The PRIME study results were highlighted at the SMFM 2025 Pregnancy Meeting, demonstrating significant improvements in neonatal outcomes.
What is the PreTRM Test?
The PreTRM Test is a blood-based biomarker assessment that predicts the risk of spontaneous preterm birth, allowing for earlier and personalized clinical interventions.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
